Study, “Oophorectomy” Can Trim Down Chances Of Breast Cancer Death By 62%


As indicated by National Cancer Institute, the detection of breast cancer with the help of mammograms among women with thick tissue is relatively complex as they have high amount of glandular and connecting tissue.

Specialists have been examining BRCA1 gene mutation and recently have carried out a study which makes it clear that the removal of ovaries can help in chopping down number of breast cancer deaths. The study has uncovered that the removal of ovaries in fact support in countering 62% of issues that is apropos with breast cancer, particularly regarding the matter of the cure of BRCA1 gene mutation cases.

A team of scientists from Women’s College Research Institute from Toronto, Canada has decided to conduct this research and concocted detailed observations. At the point when diagnosed with BRCA1 or BRCA2, women have much higher chances of having breast cancer amid the later phase of their life. It is also likely that their second breast will likewise be affected and may develop ovarian cancer in the end.

The specialists have closely mulled over 676 women who have been diagnosed with BRCA1 and BRCA2 gene mutation and most of them already had developed breast cancer in the early stages.

The process of removing ovaries is known as “Oophorectomy” and among the ones who has been examined, 345 of them have experienced the surgery, while the rest 331 has been able save both of their ovaries. Boss Editor, Dr. Mary L. Disis, JAMA Oncology published this study and the specialists said that the consequences of the potential oophorectomy had been dynamite.

The survival benefits of women with breast cancers are higher when the ovaries are removed due to estrogen receptors.

The scientists have at long last found that carrying out oophorectomy is the best alternative available for surviving the lethal disease that breast cancer is. It is also proposed that this procedure is implemented as measurement for the current treatments for the diagnosis of BRCA mutation carriers, with breast cancers that are at an early stage.

The study pose limitation such as women with breast cancer cases in Stage 1 and 2 only had gone through an assessment and analysis. Advanced stage patients have not yet been assessed.

Leave a Reply

Your email address will not be published. Required fields are marked *